行情

HEPA

HEPA

Hepion制药
NASDAQ

实时行情|Nasdaq Last Sale

1.100
-0.060
-5.17%
盘后: 1.110 +0.01 +0.91% 19:00 01/18 EST
开盘
1.140
昨收
1.160
最高
1.152
最低
1.080
成交量
82.75万
成交额
--
52周最高
3.180
52周最低
1.080
市值
8,384.78万
市盈率(TTM)
-1.7380
分时
5日
1月
3月
1年
5年
The Daily Biotech Pulse: Glaukos Gets FDA Nod, Neurocrine Preannounces Soft Ingrezza Sales, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Benzinga · 01/07 12:34
BRIEF-Hepion Pharmaceuticals Announces USAN Selection Of "Rencofilstat" As Nonproprietary Name For CRV431
reuters.com · 01/06 22:34
Hepion Pharmaceuticals to Present Clinical Data at NASH-TAG Conference
- Oral Presentation Chosen as a “Distinguished” Abstract -EDISON, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic dr...
GlobeNewswire · 01/05 13:30
FDA clears Hepion Pharma's CRV431 application for liver cancer
Hepion Pharmaceuticals (NASDAQ:HEPA) announces that the FDA has accepted its investigational new drug (IND) application for CRV431, a liver-targeting, novel cyclophilin inhibitor, for the treatment of hepatocellular carcinoma (HCC). Shares up
Seekingalpha · 2021/12/21 13:51
BRIEF-Hepion Pharmaceuticals Announces FDA Clearance Of Ind Application For CRV431 In The Treatment Of Liver Cancer
reuters.com · 2021/12/21 13:06
Hepion Pharmaceuticals gets FDA fast track designation for CRV431 to treat liver disease
The U.S. Food and Drug Administration granted fast track designation to Hepion Pharmaceuticals (HEPA) lead drug candidate CRV431 to treat non-alcoholic steatohepatitis (NASH), a type of liver disease. “CRV431 has been
Seekingalpha · 2021/11/30 13:56
VIR, HEPA and POLA among pre market gainers
Cumberland Pharmaceuticals CPIX +90% on FDA label expansion for pain therapy Pioneer Power Solutions (NASDAQ:PPSI) +66%. First Wave BioPharma (NASDAQ:FWBI) +53% announces independent data monitoring committee provides positive interim safety assessment for...
Seekingalpha · 2021/11/30 13:28
Hepion Pharmaceuticals Receives FDA Fast Track Designation For CRV431 For The Treatment Of NASH
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic
Benzinga · 2021/11/30 13:08
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解HEPA最新的财务预测,通过HEPA每股收益,每股净资产,每股现金流等数据分析Hepion制药近期的经营情况,然后做出明智的投资选择。
分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

0.00%强力推荐
100.00%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测HEPA价格均价为5.50,最高价位6.00,最低价为5.00。
最高6.00
均价5.50
最低5.00
现价1.100
EPS
实际EPS
预期EPS
-0.23-0.17-0.12-0.06
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 52
机构持股: 781.41万
持股比例: 10.25%
总股本: 7,622.53万
类型机构数股数
增持
7
18.99万
建仓
5
6.89万
减持
15
222.47万
平仓
11
99.10万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-4.74%
制药与医学研究
-1.37%
高管信息
Non-Executive Chairman/Independent Director
Gary Jacob
Chief Executive Officer/Chief Scientific Officer/Director
Robert Foster
Chief Financial Officer
John Cavan
Other
Todd Hobbs
Independent Director
Timothy Block
Independent Director
John Brancaccio
Independent Director
Arnold Lippa
Independent Director
Petrus Wijngaard
暂无数据
HEPA 简况
Hepion Pharmaceuticals, Inc. 是一家临床阶段的生物制药公司。该公司专注于开发治疗慢性肝病的药物疗法。这种治疗方法针对与非酒精性脂肪性肝炎(NASH)、病毒性肝炎和其他肝脏疾病相关的纤维化和肝细胞癌(HCC)。该公司的亲环蛋白抑制剂CRV431有利于解决这些多种复杂的病理。CRV431是一种泛环亲环蛋白抑制剂,靶向涉及肝病发展过程的多种病理途径。该公司创建了一个名为AI-POWR的人工智能平台,代表人工智能精准医学组学世界数据库访问和响应以及临床结果。该平台有助于确定哪些NASH患者对CRV431反应最好,从而可能缩短开发时间并增加安慰剂组和治疗组之间的差异性。

微牛提供Hepion Pharmaceuticals Inc(NASDAQ-HEPA)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的HEPA股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易HEPA股票基本功能。